Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Cholangiocarcinoma × Capecitabine × Clear all

Phase

Status

Sponsor Class

OTHER 21 INDUSTRY 6 NIH 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 7 Stomach Neoplasms 5 Nasopharyngeal Carcinoma 4 Colorectal Neoplasms 4 Breast Neoplasms 4 Esophageal Neoplasms 3 Neoplasm Metastasis 2 Colonic Neoplasms 2 Adenocarcinoma 2 Triple Negative Breast Neoplasms 1 Pancreatic Neoplasms 1 Oesophagogastric Cancer 1 Neuroendocrine Tumors 1 Nasopharyngeal Neoplasms 1 Mid-low Rectal Cancer 1 Metastatic Breast Cancer in the Brain 1 Locally Advanced Rectal Cancer With Liver Metastases 1 Locally Advanced Rectal Cancer 1 Liver Metastases of Colorectal Cancer 1 Immunotherapy 1 HER2 Positive Metastatic Breast Cancer 1 Colorectal Cancer Liver Metastasis 1 Cholangiocarcinoma 1 Breast Cancer Metastatic 1 Advanced Breast Cancer 1

Interventions

Gemcitabine 2 Everolimus 2 sintilimab 1 S 1 (combination) 1 Radiofrequency Ablation 1 Radiation 1 Neoadjuvant Therapy 1 Endoscopic Ultrasound-Guided Fine Needle Aspiration 1 Congresses as Topic 1 Capecitabine 1 Ambulatory Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05207735 2022-01-26

SCRCA

Henan Cancer Hospital

Phase 2 Unknown

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡